News and Events August 2021: BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient Read More » June 2021: BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection Read More » June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist Read More » April 2021: Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases Read More » March 2021: BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment Read More » March 2021: KYW InDepth Podcast – Vaccines are just part of the battle. Good therapeutics are needed to fight COVID-19 as well. Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Next » March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More » March 27-28, 2025: MedInvest Biotech & Pharma Investor Conference Learn More » Articles: Insights, intelligence and opinions from our experts. A Pioneering Biotech Promises to Revolutionize Medicine with a Human Protein that Boosts the Body’s Immune System BioAegis Therapeutics expects to unlock the healing powers of gelsolin and develop new treatments for disease. Host-directed Therapeutics for the Next Pandemic: What They Are and Why We'll Need Them by Dr. Lester Kobzik, Chief Scientific Advisor and Professor (emeritus) of Pathology at The Harvard Medical School Sepsis: The Hydra Within Us As Wallstreet Funding for Sepsis Research has Evaporated US Government Funding Picks Up the Slackby Steven Cordovano, Co-founder, VP Business Development Vaccines Alone Are Not The Answer The US is overlooking Covid’s main culprit — the threat that vaccines do not address.by Susan L. Levinson, PhD., Co-founder and CEO
August 2021: BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient Read More »
June 2021: BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection Read More »
June 2021: EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year 2021 New Jersey Award Finalist Read More »
April 2021: Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases Read More »
March 2021: BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment Read More »
March 2021: KYW InDepth Podcast – Vaccines are just part of the battle. Good therapeutics are needed to fight COVID-19 as well. Read More »
March 18-21, 2025: 44th Annual International Symposium on Intensive Care and Emergency Medicine (ISICEM) Learn More »